Last updated: February 20, 2026
What is APIXABAN?
APIXABAN (generic: BY 365, Eliquis) is an oral anticoagulant approved by multiple regulators, including the FDA and EMA. It inhibits factor Xa, a key component in the coagulation cascade, reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), and preventing deep vein thrombosis (DVT) and pulmonary embolism (PE).
Global Market Size and Growth Rate
The global direct oral anticoagulant (DOAC) market, including APIXABAN, was valued at approximately USD 12.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8% to 10% through 2030, driven by expanding indications, aging populations, and increasing prevalence of atrial fibrillation and thromboembolic disorders.
| Year |
Market Size (USD billion) |
CAGR (2022–2030) |
Source |
| 2022 |
12.5 |
— |
[1] |
| 2025 |
16.4 |
~8.6% |
Estimated |
| 2030 |
22.8 |
— |
[1], analyst estimates |
Current Market Leaders
Eliquis (APIXABAN), marketed by Pfizer and Bristol-Myers Squibb, holds approximately 60% of the DOAC market share globally. Key competitors include:
- Xarelto (rivaroxaban, Bayer/J&J)
- Savaysa/Esrest (edoxaban, Daiichi Sankyo)
Eliquis's competitive position derives from clinical efficacy, safety profile, and physician familiarity.
Sales Projections for APIXABAN
Sales forecasts assume continued market penetration, added indications, and generic entry timelines.
| Year |
Estimated Sales (USD billion) |
Assumptions |
| 2023 |
9.3 |
One-year post-launch, maintained market share |
| 2025 |
11.5 |
Increased adoption, expanded indications, steady competition |
| 2030 |
16.0 |
Market saturation, new formulation approvals, generics entering |
Drivers of Growth
- Expansion into additional indications such as venous thromboembolism (VTE) treatment.
- Use in patients with special populations (e.g., renal impairment).
- Increasing global adoption, especially in emerging markets.
- Patent protection till approximately 2030; generic entry expected thereafter may depress prices and sales.
Market Challenges
- Patent expiry, anticipated around 2029–2030.
- Competition from biosimilars and generics.
- Cost concerns influencing payer and physician adoption.
- Regulatory challenges in expanding indications.
Regional Breakdown
| Region |
Current Market Share |
Growth Drivers |
| North America |
55% |
High prevalence of AF, strong healthcare infrastructure |
| Europe |
25% |
Growing adoption, aging population |
| Asia-Pacific |
15% |
Increasing healthcare investments, rising AF prevalence |
| Rest of World |
5% |
Expanding access, regulatory approvals |
Strategic Risks and Opportunities
Risks:
- Price pressure post-patent expiration.
- Competitive launches or improved formulations.
- Regulatory delays in new indications.
Opportunities:
- Launch of combination therapies.
- Digital health integration for adherence.
- Regional expansion in emerging markets.
Key Takeaways
- The APIXABAN market is projected to grow to USD 16 billion by 2030.
- Eliquis dominates with approximately 60% market share, driven by clinical data and physician preference.
- Patent expiration around 2030 may lead to significant revenue declines unless new indications or formulations are approved.
- Growth is tempered by competitive pressures, cost considerations, and regulatory hurdles.
- Regional markets exhibit distinct growth trajectories, with significant potential in Asia-Pacific.
FAQs
1. When does patent protection on APIXABAN expire?
Patent protection in major markets, including the US and EU, is expected to extend into 2030, with some patents possibly expiring in 2029.
2. What are the main competing drugs?
Xarelto (rivaroxaban) and Savaysa/Edoxaban are the primary alternatives, both of which have similar indications.
3. Are there new indications for APIXABAN in development?
Yes, ongoing trials investigate its use for conditions like coronary artery disease and secondary stroke prevention.
4. How might biosimilar entry impact APIXABAN sales?
Post-patent expiry, biosimilars and generics are expected to reduce prices and sales, depending on regional regulatory pathways.
5. How does regional adoption influence global sales?
Regions like North America and Europe drive early adoption; expansion into emerging markets offers substantial growth opportunities.
References
[1] Grand View Research. (2023). Direct oral anticoagulants market size, share & trends analysis report.
